Advertisement

Meyka AI - Contribute to AI-powered stock and crypto research platform
Meyka Stock Market API - Real-time financial data and AI insights for developers
Advertise on Meyka - Reach investors and traders across 10 global markets
Loading...

Evotec SE

EVT.SWSIX
Healthcare
Drug Manufacturers - Specialty & Generic
CHF26.96
CHF0.00(0.00%)
Swiss Market is Open • 12:17

Evotec SE Fundamental Analysis

Evotec SE (EVT.SW) shows weak financial fundamentals with a PE ratio of -4.81, profit margin of -21.02%, and ROE of -18.11%. The company generates $0.8B in annual revenue with N/A year-over-year growth of N/A.

Key Strengths

Current Ratio2.12

Areas of Concern

ROE-18.11%
Operating Margin-11.30%
Cash Position4.95%
PEG Ratio2.09
We analyze EVT.SW's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -13.4/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-13.4/100

We analyze EVT.SW's fundamental strength across five key dimensions:

Efficiency Score

Weak

EVT.SW struggles to generate sufficient returns from assets.

ROA > 10%
-8.97%

Valuation Score

Moderate

EVT.SW shows balanced valuation metrics.

PE < 25
-4.81
PEG Ratio < 2
2.09

Growth Score

Weak

EVT.SW faces weak or negative growth trends.

Revenue Growth > 5%
N/A
EPS Growth > 10%
N/A

Financial Health Score

Excellent

EVT.SW maintains a strong and stable balance sheet.

Debt/Equity < 1
0.61
Current Ratio > 1
2.12

Profitability Score

Weak

EVT.SW struggles to sustain strong margins.

ROE > 15%
-1811.45%
Net Margin ≥ 15%
-21.02%
Positive Free Cash Flow
No

Key Financial Metrics

Is EVT.SW Expensive or Cheap?

P/E Ratio

EVT.SW trades at -4.81 times earnings. This suggests potential undervaluation.

-4.81

PEG Ratio

When adjusting for growth, EVT.SW's PEG of 2.09 indicates potential overvaluation.

2.09

Price to Book

The market values Evotec SE at 0.96 times its book value. This may indicate undervaluation.

0.96

EV/EBITDA

Enterprise value stands at -4.84 times EBITDA. This is generally considered low.

-4.84

How Well Does EVT.SW Make Money?

Net Profit Margin

For every $100 in sales, Evotec SE keeps $-21.02 as profit after all expenses.

-21.02%

Operating Margin

Core operations generate -11.30 in profit for every $100 in revenue, before interest and taxes.

-11.30%

ROE

Management delivers $-18.11 in profit for every $100 of shareholder equity.

-18.11%

ROA

Evotec SE generates $-8.97 in profit for every $100 in assets, demonstrating efficient asset deployment.

-8.97%

Following the Money - Real Cash Generation

Operating Cash Flow

Evotec SE generates limited operating cash flow of $1.41M, signaling weaker underlying cash strength.

$1.41M

Free Cash Flow

Evotec SE generates weak or negative free cash flow of $-89.39M, restricting financial flexibility.

$-89.39M

FCF Per Share

Each share generates $-0.50 in free cash annually.

$-0.50

FCF Yield

EVT.SW converts -11.62% of its market value into free cash.

-11.62%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-4.81

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

2.09

vs 25 benchmark

P/B Ratio

Price to book value ratio

0.96

vs 25 benchmark

P/S Ratio

Price to sales ratio

1.01

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.61

vs 25 benchmark

Current Ratio

Current assets to current liabilities

2.12

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-0.18

vs 25 benchmark

ROA

Return on assets percentage

-0.09

vs 25 benchmark

ROCE

Return on capital employed

-0.06

vs 25 benchmark

How EVT.SW Stacks Against Its Sector Peers

MetricEVT.SW ValueSector AveragePerformance
P/E Ratio-4.8128.48 Better (Cheaper)
ROE-18.11%777.00% Weak
Net Margin-21.02%-20226.00% (disorted) Weak
Debt/Equity0.610.30 Weak (High Leverage)
Current Ratio2.124.66 Strong Liquidity
ROA-8.97%-14638.00% (disorted) Weak

EVT.SW outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Evotec SE's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

N/A

Industry Style: Defensive, Growth, Innovation

EPS CAGR

N/A

Industry Style: Defensive, Growth, Innovation

FCF CAGR

N/A

Industry Style: Defensive, Growth, Innovation

Fundamental Analysis FAQ